Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. (NYSE: VEEV) is a cloud software company focused on the global life sciences industry, and its news flow reflects activity across commercial, R&D, quality, and corporate initiatives. Company announcements frequently highlight new product capabilities in its industry cloud for life sciences, including developments in Veeva AI, Vault CRM, Veeva Development Cloud, Veeva Quality Cloud, and solutions such as Veeva Environmental Monitoring and Veeva Basics.
Investors and industry professionals following VEEV news can see updates on strategic partnerships with major life sciences companies, such as long-term enterprise agreements and expanded use of Vault CRM by large pharmaceutical and biopharmaceutical organizations. Veeva also issues releases on its work with emerging biotechs, including adoption of Veeva Basics to standardize operations across clinical, regulatory, and quality.
Veeva’s news includes information on AI-driven capabilities like Veeva AI Agents for Vault CRM and PromoMats, covering agents such as Free Text Agent, Voice Agent, Pre-call Agent, Quick Check Agent, and Content Agent. These updates describe how the company embeds industry-specific AI into its applications to support productivity, compliance, and customer engagement in life sciences.
In addition, Veeva regularly publishes earnings results, financial outlooks, and capital allocation decisions, such as the authorization of a share repurchase program reported in an 8-K filing. The company also announces participation in investor conferences and provides details on its role as a Public Benefit Corporation. This news page aggregates these releases so readers can track product milestones, customer agreements, AI developments, financial updates, and corporate governance disclosures related to VEEV.
Veeva Systems reported total revenues of $2,155.1 million for FY 2023, reflecting a 16% increase year-over-year. Q4 revenues reached $563.4 million, also up 16%. Subscription services revenues were $1,733.0 million for FY 2023, +17%, with Q4 at $460.2 million, rising 16%. While Q4 net income surged 94% to $188.5 million, operating income fell 9% year-over-year. Veeva anticipates FY 2024 revenues of $2,350-$2,360 million and a non-GAAP net income per share of $4.33. CEO Peter Gassner highlighted strong customer growth with 1,388 customers as of the fiscal year end.
Summary not available.
Veeva Systems (NYSE: VEEV) reported increased adoption of Veeva Vault EDC, with six out of the top twenty pharmaceutical companies opting for this solution to improve clinical data management. The system allows for significant time and cost savings, enhancing the overall research site experience. Vault EDC provides agile tools to manage trial complexity, facilitating faster study builds and amendments. Feedback from industry leaders indicates a 30-35% improvement in study build timelines. Veeva remains committed to advancing clinical data management through innovative solutions, with a focus on operational excellence and customer success.
Veeva Systems (NYSE: VEEV) announced the successful adoption of its Vault PromoMats platform by major biopharma companies, accelerating the medical, legal, and regulatory review processes. Eight out of the top ten biopharmas are leveraging this technology, resulting in a more than 50% reduction in time to market and a 40% increase in content reuse. Notable partners such as Novo Nordisk and Boehringer Ingelheim highlighted enhanced efficiency and personalized content delivery through modular strategies. These innovations are critical in driving impactful engagements across various channels and geographies.
Veeva Systems (NYSE: VEEV) is scheduled to announce its fourth quarter and full fiscal year results for the period ending January 31, 2023 after market close on March 1, 2023. A conference call and webcast will take place at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. Prepared remarks will be available on the investor relations website at ir.veeva.com at approximately 1:05 p.m. PT (4:05 p.m. ET).
Veeva is the global leader in cloud software for the life sciences sector, serving over 1,000 customers, including top pharmaceutical firms and emerging biotech companies.
Veeva Systems (NYSE: VEEV) announced that Adare Pharma Solutions selected the Veeva Vault Quality Suite to streamline quality processes across its operations in the U.S., France, and Italy. This integration will replace legacy systems, enhance collaboration, and improve visibility for customers. The suite includes Veeva Vault QMS for managing quality processes, Vault QualityDocs for document control, and Vault Training for employee qualifications. This partnership aims to support Adare's goals in delivering improved services and transformational medicines.
On January 10, 2023, Veeva Systems (NYSE: VEEV) expressed its support for the FTC's proposed rule to ban non-compete agreements, citing their detrimental effects on innovation and employee rights. Veeva argues that non-competes restrict talent mobility, hinder entrepreneurship, and ultimately harm economic growth and product quality. The company has a history of opposing such agreements and has never required its employees to sign them. CEO Peter Gassner emphasized that banning non-competes is crucial for fostering a competitive and innovative workforce. Veeva aims to eliminate non-competes by 2030 as part of its Public Benefit Corporation mission.
Veeva Systems (NYSE: VEEV) announced that CEO Peter Gassner will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 2:15 p.m. PT in San Francisco. The presentation will be available via live and archived webcast on Veeva's investor relations website.
Veeva is a leader in cloud software for the life sciences industry, serving over 1,000 customers including major pharmaceutical firms and emerging biotech companies.
On December 14, 2022, Veeva Systems announced that Dan Crawford, principal consultant of Veeva Clinical Database, has been elected chair of the CDISC Advisory Council. His role will involve collaborating with top pharma leaders and advising the CDISC board on data standards. Crawford aims to enhance data collection and promote the benefits of CDISC standards, which help expedite clinical trials and regulatory processes. This leadership position reflects Veeva's commitment to innovation in life sciences data management.
Veeva Systems reported total revenues of $552.4 million for Q3 2023, reflecting a 16% year-over-year increase. Subscription services also rose to $441.6 million, marking the same growth rate. Operating income decreased by 9% to $121.4 million, whereas non-GAAP operating income grew 10% to $219.5 million. Net income increased by 2% to $108.5 million and non-GAAP net income surged 16% to $183.2 million. The company also established a 10-year strategic partnership with Merck.